Navigation Links
Westaim announces 2007 third quarter results

Company to seek buyer for iFire Technology Corp.

CALGARY, Nov. 13 /PRNewswire-FirstCall/ - The Westaim Corporation announced today that for the third quarter ended September 30, 2007, it recorded a net loss of $17.1 million or 18 cents per share, on revenues of $7.8 million. In the same quarter last year, the company recorded a net loss of $9.6 million, or 10 cents per share, on revenues of $8.2 million.

In the third quarter of 2007, the Company recorded reorganization costs including severance, of $2.3 million related to operational changes that will significantly reduce the Company's annual operating costs. In addition, in the third quarter, the Company wrote down its investment in Canadian third-party asset-backed commercial paper (ABCP) by $3.0 million.

For the nine months ended September 30, 2007, the Company posted a net loss of $31.2 million or 33 cents per share on revenues of $20.7 million. For the same period in 2006, Westaim reported a net loss of $39.5 million or 42 cents per share on revenues of $22.5 million. Results in 2007 benefited from an $8.6 million gain on the sale of real estate and a dilution gain of $4.5 million reported earlier in the year. These benefits have been partially offset by corporate restructuring costs of $6.6 million incurred in 2007.

At September 30, 2007, Westaim had $32.6 million in consolidated cash and short-term investments. Westaim's cash position, excluding cash and short-term investments held by its 74.6 per cent owned affiliate NUCRYST Pharmaceuticals Corp., was $12.2 million. In addition, Westaim held third-party ABCP with a book value of $14.1 million. As previously reported, the market for $35 billion of third-party ABCP has been frozen since mid-August and until the paper is restructured, or a market otherwise forms for this ABCP, Westaim cannot be certain of the ultimate value it will realize for its holdings.

The Company announced on November 2, 2007 the receipt of an offer, subject to final documentation, for a credit line of $12.6 million from a major financial institution. The credit facility will be available for one year and will be secured by the equivalent value of ABCP held by the Company.

Westaim also announced today that it will actively seek a buyer for its iFire subsidiary. The Company will immediately freeze the development effort on iFire's thick dielectric electroluminescent (TDEL) technology during the sale process, which will reduce iFire's operating costs by approximately 50 percent.

"Despite continued progress in certain aspects of its development plan, iFire's overall progress has been slower than expected. With increasingly demanding specification improvement targets in the flat panel TV market in general, our product development timeline has been extended past the timeframe we had originally expected," said Drew Fitch, President and CEO of The Westaim Corporation. "Westaim continues to believe in the potential of iFire's TDEL technology; however, we do not have the financial resources required to complete the development work necessary for commercialization. We will continue to assess the structure of the Company as the sale process develops."

The Westaim Corporation's technology investments include iFire Technology Corp., which is developing a low-cost flat panel display, and a 74.6 per cent interest in NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX; NCS), which develops, manufactures and commercializes medical products that fight infection and inflammation based on its nanocrystalline silver technology. Westaim's common shares are listed on The Toronto Stock Exchange under the trading symbol WED.

This news release contains forward-looking statements. These statements are based on current expectations that are subject to risks and uncertainties, and Westaim can give no assurance that these expectations are correct. Various factors could cause actual results to differ materially from those projected in such statements, including but not limited to statements regarding the ultimate value of Westaim's asset-backed commercial paper, the availability of credit, reduction of operating costs, product development timelines and the work necessary for the commercialization of iFire's technology, the potential of iFire's technology, Westaim's financial resources, and the potential sale of iFire. Westaim disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise. Accordingly, readers are advised not to place undue reliance on forward-looking statements, and should not rely on this information at any date other than the date of this news release. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.


Financial Highlights


(thousands of dollars except per share data)


Three Months Ended Nine Months Ended

September 30 September 30

Consolidated Statements --------------------- ---------------------

of Operations 2007 2006 2007 2006


Revenue $ 7,839 $ 8,203 $ 20,656 $ 22,451

Net loss (17,138) (9,552) (31,226) (39,538)

Net loss per common share

- basic and diluted (0.18) (0.10) (0.33) (0.42)

Weighted average number of

common shares outstanding

(thousands) 94,098 93,944 94,047 93,369


Three Months Ended Nine Months Ended

September 30 September 30

--------------------- ---------------------

Segmented Information 2007 2006 2007 2006



Nucryst Pharmaceuticals $ 7,839 $ 8,203 $ 20,656 $ 22,451



Operating loss

Nucryst Pharmaceuticals $ (195) $ (2,638) $ (4,167) $ (9,016)

iFire Technology (8,358) (8,443) (26,982) (28,731)

Other (including

corporate costs) (4,194) 229 (8,979) (4,817)


Operating loss $ (12,747) $ (10,852) $ (40,128) $ (42,564)



Consolidated September December

Balance Sheets 30, 2007 31, 2006


Cash and short-term

investments $ 32,645 $ 62,832

Current assets 51,247 80,256

Other assets 64,099 68,083

Current liabilities 13,701 15,797

Shareholders' equity 82,680 112,977

SOURCE Westaim Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. The Westaim Corporation update on status of short-term investments
2. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Third Quarter Results
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... successful and prominent nonprofit healthcare organizations in the country. They have overseen financial ... organizations, and helped advance the healthcare industry as a whole through their advocacy ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, ... choose to buy during the Black Friday and Cyber Monday massage chair sales ... search the Internet high and low to find the best massage chair deals, they ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is ... 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an ... every day excited to rebuild lives and it’s an honor to have served all ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast cancers found ... mammography, according to a study published online in the journal Radiology. Researchers said ... may necessitate a change in treatment. , Breast MRI is the most sensitive ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the German ...
(Date:11/26/2015)... Research and Markets ( ) has ... Market by Type (Dressings, Therapy Devices, Active Wound Care), ... Facility), and Geography - Global Forecast to 2020" ... --> The purpose of this report ... the global advanced wound care market. It involves deep ...
(Date:11/26/2015)... 26, 2015 ... adds "Global Repaglinide Industry 2015 ... on China Repaglinide Market, 2010-2019" reports ... and information to its online business ... . --> ...
Breaking Medicine Technology: